Crystal forms of rifaximin and their effect on pharmaceutical properties
| Autor: | Marco Polito, Giuseppe Claudio Viscomi, D. Confortini, Fabrizia Grepioni, Miriam Barbanti, Goffredo Rosini, Dario Braga, M. Campana, Paolo Righi, Vincenzo Cannata |
|---|---|
| Přispěvatelé: | G. C. Viscomi, M. Campana, M. Barbanti, F. Grepioni, M. Polito, D. Confortini, G. Rosini, P. Righi, V. Cannata, D. Braga |
| Rok vydání: | 2008 |
| Předmět: |
Chemistry
solubility perspective General Chemistry Crystal structure in-vitro rifampicin Condensed Matter Physics sample polymorphism Bioavailability Rifaximin resistance Crystal Crystallography chemistry.chemical_compound Polymorphism (materials science) impact General Materials Science Solubility absorption Dissolution Powder diffraction |
| Zdroj: | CrystEngComm. 10:1074 |
| ISSN: | 1466-8033 |
| DOI: | 10.1039/b717887e |
| Popis: | Five distinct crystal forms of rifaximin (α, β, γ, δ and e) have been identified and characterised by X-ray powder diffraction, solid state 13C NMR, and HATR-IR spectroscopy. Changes in the crystal structure may produce differences of two to three orders of magnitude in the rate of intrinsic dissolution, solubility and bioavailability of rifaximin. Alteration of the pharmacokinetic parameters is of particular interest; the Cmax values of the crystal forms range from 1.1 to 1085.31 ng ml−1 and the AUC0-24 h values range from 10 to 4795 ng h ml−1. These findings are relevant to the therapeutic use of rifaximin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|